Incyte Corp

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics across three key franchises: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its flagship product, Jakafi (ruxolitinib), is a JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, with a recently approved once-daily extended-release formulation (Jakafi XR). Opzelura (ruxolitinib cream) is approved for atopic dermatitis and vitiligo in the U.S. and vitiligo in Europe. The company's oncology and hematology portfolio includes Monjuvi/Minjuvi (tafasitamab) for lymphomas, Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms, Zynyz (retifanlimab) for squamous cell carcinoma of the anal canal and Merkel cell carcinoma, Niktimvo (axatilimab) for chronic GVHD, and Iclusig (ponatinib) for leukemia in Europe. Incyte maintains an extensive clinical pipeline including INCA033989 (mutCALR) for myeloproliferative neoplasms, INCB161734 (KRASG12D) for pancreatic and colorectal cancers, INCA33890 (TGFβR2xPD-1) for colorectal cancer, INCB123667 (CDK2) for ovarian cancer, povorcitinib (TYK2/JAK1 inhibitor) for hidradenitis suppurativa and prurigo nodularis, and latarcibart for von Willebrand disease acquired through the Vega Therapeutics acquisition. The company commercializes its products globally, with direct operations in the U.S., Europe, Japan, and other international markets. Updated Oct 8, 2026